In this work, a microfluidic immunosensor chip was developed
by
incorporating microfluidic technology with electrochemiluminescence
(ECL) for sensitive detection of human epidermal growth factor receptor-2
(HER2). The immunosensor chip can achieve robust reproducibility in
mass production by integrating multiple detection units in a series.
Notably, nanoscale materials can be better adapted to microfluidic
systems, greatly enhancing the accuracy of the immunosensor chip.
Ag@Au NCs closed by glutathione (GSH) were introduced in the ECL microfluidic
immunosensor system with excellent and stable ECL performance. The
synthesized CeO2–Au was applied as a coreaction
promoter in the ECL signal amplification system, which made the result
of HER2 detection more reliable. In addition, the designed microfluidic
immunosensor chip integrated the biosensing system into a microchip,
realizing rapid and accurate detection of HER2 by its high throughput
and low usage. The developed short peptide ligand NARKFKG (NRK) achieved
an effective connection between the antibody and nanocarrier for improving
the detection efficiency of the sensor. The immunosensor chip had
better storage stability and sensitivity than traditional detection
methods, with a wide detection range from 10 fg·mL–1 to 100 ng·mL–1 and a low detection limit
(LOD) of 3.29 fg·mL–1. In general, a microfluidic
immunosensor platform was successfully constructed, providing a new
idea for breast cancer (BC) clinical detection.